Massachusetts medical device giant Boston Scientific (NYSE:BSX) today announced FDA approval for the latest in its line of coronary stents, the Rebel bare-metal stent.
The Rebel device is essentially a drug-free version of Boston Scientific’s popular Promus Premier stent, featuring the same platinum chromium material and is the same architecture. The stent comes in a suite of 46 sizes, from 2.25 mm to 4.5 mm and lengths of 8 mm to 32 mm, the company said.
"This new bare-metal stent has the same great visibility and deliverability as the Premier [drug-eluting stent] but allows me to treat patients who are not candidates for DES therapy," Medstar Union Memorial Hospital’s Dr. John Wang said on behalf of the company. "The platinum chromium architecture provides great radial strength with low recoil, which is particularly important in patients receiving bare-metal stents."
Wang presented Rebel data earlier this year at the Cardiovascular Research Technologies conference in Washington D.C., around the time the device was approved for the European Union.
"Launching the Rebel Stent System in the U.S. is another important step to ensure that we offer physicians the most differentiated and broadest product portfolio possible," Boston Scientific interventional cardiology president Kevin Ballinger said in prepared remarks.